You are here

Article Text

Article menu
Download PDFPDF
DTB Select
Triple inhaled therapy versus dual inhaled therapy for COPD

https://doi.org/10.1136/dtb.2018.000048

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Lipson DA et al. Once daily single-inhaler triple versus dual therapy in patients with COPD. New Engl J Med 2018;378:1671–80.

    Key learning points

    • A clinical trial compared single inhaler triple therapy with two forms of single inhaler dual therapy in people with COPD.

    • Ten people would need to be treated with triple therapy instead of LAMA/LABA therapy for 1 year to prevent one moderate or severe exacerbation.

    • Twenty people would need to be treated with triple therapy instead of LAMA/LABA therapy for 1 year to prevent one severe exacerbation.

    • There would be one additional case of pneumonia for every 35 people treated with triple therapy instead of LAMA/LABA therapy for 1 year.

    Inhaled triple therapy for chronic obstructive pulmonary disease (COPD) resulted in a reduction in moderate or severe exacerbations and an increase in the risk of pneumonia …

    View Full Text

    Footnotes

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Contributors DTB Team.